CDK9 and B-cell chronic lymphocytic leukemia: We also describe the preclinical evaluation of the potent cdk9 inhibitor, CDKI-73 in primary CLL cells and detail its potential as a clinical agent both as a single agent and in combination with the purine nucleoside analog fludarabine.